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Background: Profound knowledge about child growth, development, health, and disease in contemporary children
and adolescents is still rare. Epidemiological studies together with new powerful research technologies present
exciting opportunities to the elucidation of risk factor-outcome associations with potentially major consequences
for prevention, diagnosis and treatment.
Aim: To conduct a unique prospective longitudinal cohort study in order to assess how environmental, metabolic
and genetic factors affect growth, development and health from fetal life to adulthood.
Methods: The ‘Leipzig Research Centre for Civilization Diseases (LIFE) Child Study’ focuses on two main research
objectives: (1) monitoring of normal growth, development and health; (2) non-communicable diseases such as
childhood obesity and its co-morbidities, atopy and mental health problems. Detailed assessments will be
conducted alongside long-term storage of biological samples in 2,000 pregnant women and more than 10,000
children and their families.
Results: Close coordination and engagement of a multidisciplinary team in the LIFE Child study successfully
established procedures and systems for balancing many competing study and ethical needs. Full participant
recruitment and complete data collection started in July 2011. Early data indicate a high acceptance rate of the
study program, successful recruitment strategies and the establishment of a representative cohort for the
population of Leipzig. A series of subprojects are ongoing, and analyses and publications are on their way.
Discussion: This paper addresses key elements in the design and implementation of the new prospective
longitudinal cohort study LIFE Child. Given the recognized need for long-term data on adverse effects on health
and protective factors, our study data collection should provide magnificent opportunities to examine complex
interactions that govern the emergence of non-communicable diseases.
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Population-based cohort studies of children and birth
cohort studies have made landmark contributions in
identifying genetic and environmental factors that influence
health and disease. In recent years, a variety of them have
been established worldwide, and more are in progress.
Important examples in Europe are the Avon Longitudinal
Study of Parents and Children (ALSPAC), the Genera-
tions R Study, the Danish National Birth Cohort (DNBC)
and the German Health Interview and Examination Survey
for Children and Adolescents (KiGGS) [1-4].
Why is there still relevance for a new population-based
cohort study?
The pace of development and change has accelerated ex-
ponentially since the beginning of the 20th century and
continues today, affecting many aspects of daily modern
life. This implies that cohort studies will always reflect
relatively contemporary exposures and practices. How-
ever, many ongoing birth cohorts began recruitment in
the last century [1,3,5]. Ethnicity, different political and
cultural backgrounds are associated with differences in
disease prevalence. For example, there are large differ-
ences in prevalence of overweight and obesity among pre-
schoolers across Europe [6]. Rapid development in
research technologies and advancements in electronic data
processing have increased the scope of what is possible to
measure and include in epidemiological investigations.
This emphasizes the need for contemporary population-
based cohort studies across different geographical regions.
Scope of research
The ‘Leipzig Research Centre for Civilization Diseases
(LIFE) Child Study’ has been designed to understand
how and through what mechanisms and mediators (epi)
genetic, metabolic and environmental factors influence
health and development in children and adolescents in
modern society. The study is a prospective, longitudinal
population-based cohort study of urban children from
fetal life until adulthood. It focuses on two main research
objectives: (1) monitoring of normal growth, develop-
ment and health; (2) non-communicable diseases such as
childhood obesity and its co-morbidities, atopy and men-
tal health problems. Under the ‘life course’ conceptual
model, risk factors during pregnancy and childhood alter
the trajectories set by these early signals thus raising or
lowering the risk of diseases. Therefore, ensuring saluto-
genic influences could entrain healthful trajectories of
energy balance for life [7].
Methods
Study area, collaboration and overview
The LIFE Child study is a prospective longitudinal
population-based cohort study with a life courseapproach to health and disease. A multi-professional
team, including paeditricians, psychologists, sociologists,
economists, psychiatrists, nutritional and sport scien-
tists, ophthalmologists and dentists, has developed the
conceptual framework of the study and established an
administrative structure for the management and imple-
mentation of the study. Extensive assessments are car-
ried out in pregnant women and their offspring and
children and their families. The study collects detailed
information from clinical examinations, questionnaires
and interviews and includes a collection of several types
of biological materials at various time points (see
Tables 1, 2, 3, 4 and 5). Prenatal examinations are con-
ducted during the 24th to 26th and 34th to 36th week of
gestation. Birth is a crucial part of the study to collect
cord blood, placental tissue and to obtain information
about the labour and delivery from medical records.
During the first year of life, data is collected from chil-
dren at 3, 6 and 12 month of age. Moreover, a represen-
tative sample of children and adolescents (up to age
17.99 years) will be approached together with their fam-
ilies. Participants will be followed annually over a period
of ten years irrespective of the age at the first participa-
tion in the study. In addition, the LIFE Child study fo-
cuses in certain disease cohorts and disease free controls
in more detail. The aim of these subgroups is to examine
aetiological associations with more in-depth methods
that cannot be applied in the whole cohort due to time,
financial and logistical constraints. So far, there are three
disease cohorts: LIFE Child OBESITY, LIFE Child DE-
PRESSION and LIFE Child ATOPY. In the future, dur-
ing the course of the study, additional disease cohorts
might be conducted.
The LIFE Child study is part of LIFE, a life sciences re-
search program of the University of Leipzig (Leipzig Re-
search Centre for Civilization Diseases - LIFE). The
measurements are performed in a well-equipped re-
search centre located on the premises of the University
Hospital of Leipzig. Big advantages are the proximity to
the Hospital for Children and Adolescents, Department
of Women and Child Health of the University of Leipzig,
the LIFE Adult cohort and the IFB (Integrated Research
and Treatment Centre Adiposity Diseases), as well as
the basic research laboratories, hence allowing close
interaction and addressing the objectives in an interdis-
ciplinary approach. The LIFE Child study maintains a
close collaborative network with the University of
Leipzig, the Centre for Paediatric Research (CPL), the
IFB, public health centres, schools and kindergartens,
the faculty of education, the institute for medical in-
formatics, statistics and epidemiology, the Helmholtz
centre for environmental research, the CrescNetW net-
work and with other national and international epidemio-
logical research groups.
Table 1 Assessments in the LIFE Child HEALTH and OBESITY cohorts
LIFE Child HEALTH cohort LIFE Child OBESITY cohort
Participant age 0-2 years 2-6 years ≥ 6 years ≥ 6 years
Anthropometry • Weight • Weight • Weight • Weight
• Height • Height and sitting height • Height and sitting height • Height and sitting height
• Head, arm, leg, waist, neck,
hip, thoracal and abdominal
circumference
• Head, arm, leg, waist, neck
and hip circumference
• Head, arm, leg, waist,
neck and hip circumference
• Head, arm, leg, waist,
neck and hip circumference
• Biparietal diameter • Skinfolds • Skinfolds • Skinfolds
• Blood pressure • Blood pressure • Blood pressure • Blood pressure
Clinical exam • Clinical history (perinatal
and past medical history,
medications, immunisations,
developmental history)
• Clinical history (perinatal
and past medical history,
medications, immunisations,
developmental history)
• Clinical history (perinatal
and past medical history,
medications, immunisations,
developmental history)
• Clinical history (perinatal




















• Dental examination including






(jaw models, dental caries,
periodontal disease, orofacial
pain, bruxism and tongue
function)
• Dental examination




Biological samples • Blood, urine and hair • Blood, urine and hair • Blood, urine and hair • Oral glucose tolerance test
• Blood, urine and hair
Questionnaires • See Table 4 • See Table 4 • See Table 4 • See Table 4
Motor and cognitive
development
• Bayley scales • Bayley scales (< 3.6 years) • Motor skills test • Motor skills test
• Motor skills test (> 3.6 years)
Imaging • Cranial ultrasound
(3rd month of life)
• 3D-Bodyscan1 • 3D-Bodyscan1
• Sonography (heart, intima
media thickness, thyroid
and kidney2, for a sub-sample)










• Endopat (for a sub-sample)
Additional
assessments
• Voice examination1 • Accelerometry










• Electrical bioimpedance analysis
• Polysomnography
(for a sub-sample)
• Eating behaviour test2
• Optical coherence tomography
and ophthalmoscopy2
Prick test1, 2
(LIFE Child ATOPY cohort)
1 The assessment is combined with a specific questionnaire. 2Planned.
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Table 2 Assessments in the parents of the LIFE Child
participants
Questionnaires and interview Other assessments:
• Clinical history Biological samples:
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The LIFE Child study will recruit a sample of 10,000
children and adolescents (LIFE Child HEALTH) and
their families and 2,000 pregnant women (LIFE Child
BIRTH) and their partners between July 2011 and July
2014. All children with their families and pregnant
women of the area of Leipzig are eligible to participate
in the LIFE Child study. This sample is supposed to rep-
resent the population of the city. The LIFE Child study
consists of three disease cohorts: The LIFE Child OBES-
ITY cohort is a sample of 1,500 obese children and ado-
lescents that will be assessed and compared to a specific
control group (N=1,500) with equally detailed phenotyping
including metabolic and cardiovascular measurements.
The LIFE Child DEPRESSION cohort is gathering data
from a sample of 800 young patients (8–14 years) with psy-
chopathological symptoms and a control sample of healthyTable 3 Assessments in the mothers of the LIFE Child BIRTH c
24th – 26th week of gestation 34th - 36th week of ges
Anthropometry • Weight • Blood pressure
• Height and sitting height
• Head, arm, leg, waist,
neck and hip circumference
• Blood pressure
Imaging • 3D-Bodyscan • 3D-Bodyscan
• Ultrasound data of fetal size • Ultrasound data of feta
Biological
samples
• Blood, urine and hair • Blood, urine and hair
• Oral glucose tolerance test
Clinical exam • Family history and
history of pregnancy
• Follow-up history of
pregnancy
• Current medications • Current medications
Questionnaires • See Table 4 • See Table 4
Evaluations during pregnancy are planned in the 24th - 26th week of gestation and
three visits in the study centre are planned.children (N=400). Both samples will be assessed by means
of a multi-informant, multi-method approach in 2-year fol-
low-ups over 10 years. In the LIFE Child ATOPY cohort
extra questionnaires and a prick test with common aller-
gens in addition to the LIFE Child HEALTH program will
be performed.
Ethical issues
The LIFE Child study like any other paediatric study
encounters complex ethical issues [8]. These include the
collection of data from minors, long-term biobanking of
biological samples and subsequent genetic and epigen-
etic analysis and data privacy. The study was designed in
accordance to the declaration of Helsinki [9]. The Ethics
Committee of the University of Leipzig was involved in
the study outline and approved the study (Reg. No. 264-
10-19042010). Fully informed and written consent is
obtained for all participants and their parents. Starting
at the age of twelve, written consent is also obtained
from the children themselves. Participants are asked to
re-consent at each study visit during complete course of
the study. Consent for long-term use of data is sought.
Moreover, participants are informed of their right to
withdraw without explanations or adverse consequences
at any time. A special two-pass encryption program is
used to generate subject identifier codes (SIC) for all
participants of the study in order to pseudo-anonymise
their data. Both an internal and an independent external
ethical advisory board have been established.
Recruitment and attrition
The LIFE Child study decided to employ a variety of re-
cruitment strategies. The overall approach is a community-ohort
tation Delivery 3rd, 6th and 12th month postpartum
• Weight
• Height and sitting height





• Cord blood, biopsies
of the placenta and
the umbilical cord
• Blood, urine and hair
• Breast milk
• Follow-up history of pregnancy
• History of delivery
• Current medications
• See Table 4
Assessments in the child (see Table 1)
in the 34th - 36th week of gestation. During the first year of their offspring’s life
Table 4 Content of questionnaires, interviews and psychological tests
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Quality of life (≥ 10
years)1
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Alternative medicine1 Alternative medicine1 Alternative medicine1
Allergies1 Allergies1 Allergies1 Allergies1











































school (≥ 6 years)1
Performance at school1 Performance at school1













Mental disorders1 Mental disorders (≥ 18
years)1
Mental disorders1 Psychiatric diagnoses2 Mental disorders1
Illness behaviour and
somatoform disorders







Personality Personality (Big five


















































Table 5 Biobank blood sample collection and parameters of direct analysis
Participant age Maximum volume of stored aliquots Direct analysis
Birth 24 x 0.3 ml (EDTA, SG) Not performed
3 Month 4 x 0.3 ml (EDTA, SG) Electrolytes, bilirubin, protein, creatinin kinase, lipid profile, full blood
count, thyroid function test, proinflammatoric cytokines, bone parameters,
vitamins, NT-pro-BNP, growth hormones
6 Month 6 x 0.3 ml (EDTA, SG) Electrolytes, bilirubin, protein, creatinin kinase, lipid profile, full blood
count, thyroid function test, proinflammatoric cytokines, bone parameters,
vitamins, allergy testing, troponin T, NT- pro-BNP, growth hormones
1 – 3 years 8 x 0.3 ml (EDTA, SG) Electrolytes, protein, creatinin kinase, lipid profile, full blood count, thyroid
function test, proinflammatoric cytokines, bone parameters,vitamins,
allergy testing, troponin T, NT- pro-BNP, growth hormones, liver function
tests, renal function tests, transferrin, sex steroids
3 ml (Blood RNA tube)
3 – 6 years 10 x 0.3 ml (EDTA, SG) Electrolytes, protein, creatinin kinase, lipid profile, full blood count, thyroid
function test, proinflammatoric cytokines, bone parameters,vitamins,
allergy testing, troponin T, NT- pro-BNP, growth hormones, liver function
tests, renal function tests, transferrin, ferritin, sex steroids
3 ml (Blood RNA tube)
4 ml (Cell preparation tube)
6 – 8 years 12 x 0.3 ml (EDTA, SG) Electrolytes, protein, creatinin kinase, lipid profile, full blood count, thyroid
function test, proinflammatoric cytokines, bone parameters,vitamins,
allergy testing, troponin T, NT- pro-BNP, growth hormones, liver function
tests, renal function tests, transferrin, glucose, insulin, sex steroids
3 ml (Blood RNA tube)
4 ml (Cell preparation tube)
LIFE Child OBESITY cohort and controls :
+ Oral glucose tolerance test, proinsulin, c-peptide, uric acid
8 – 14 years 20 x 0.3 ml (EDTA, SG) See 6 – 8 years
3 ml (Blood RNA tube)
8 ml (Cell preparation tube)
> 14 years 26 x 0.3 ml (EDTA, SG) See 6 – 8 years
3 ml (Blood RNA tube)
8 ml (Cell preparation tube)
Parents 24 x 0.3 ml (EDTA, SG) Not performed
3 ml (Blood RNA tube)
8 ml (Cell preparation tube)
Pregnant Women
(24th - 26th week of gestation,
34th - 36th week of gestation
and visits postpartum)
30 x 0.3 ml (EDTA, SG) Electrolytes, protein, creatinin kinase, lipid profile, full blood count, thyroid
function test, proinflammatoric cytokines, bone parameters,vitamins,
allergy testing, growth hormones, liver function tests, renal function tests,
transferrin,glucose, insulin, sex steroids, oral glucose tolerance test
3 ml (Blood RNA tube)
8 ml (Cell preparation tube)
34th -36th week of gestation: no oral glucose tolerance test
Visits postpartum: no renal function tests
Number of samples x volume collection. EDTA, Ethylene-Diamine-Tetra-Acetic acid tube. SG, Serum Gel tube. LH, Lithium Heparin tube. NT-pro-BNP, N-terminal
pro-Brain Natriuretic Peptide. RNA, Ribonucleic acid.
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clinics, public health centres, kindergartens, schools and
partner study centres like the IFB (see Figures 1, 2 and 3).
Specific contact information is given to participants at the
time of recruitment. Telephone and email reminders are
performed. A variety of items embossed with the study logo
(see Figure 4), a green amphibian, as well as small monetary
incentives (not more than 20 Euro per child) are given to
participants at the time of recruitment to compensate for
their time [10]. Pregnant women are also offered an ultra-
sound video of their baby. Recruitment goals are continu-
ously monitored and strategies are adapted. The
researchers send Christmas and birthday cards and newslet-
ters to encourage continued participation. Study promotionlike presentations, forums, fliers/posters, press releases and
TV spots is targeted at potential participants. Regular feed-
back on results will be provided. As retention involves
building relationships with participants several events like
children’s parties and sport events (e.g. running) are
arranged. Several German cohort studies have already
shown high enrolment and follow-up rates. This might be
due to the fact that the German population, especially in
East Germany, is apparently more compliant with the par-
ticipation in research projects in comparison with other
countries [5,11]. People who voluntarily contact the study
centre for participation tend to be different from other
people in terms of basic demographic factors (e.g. social
class, level of education and core personality traits). To
Figure 1 Strategies of recruitment. Strategies of recruitment and favoured sampling sizes depending on the age at the first participation.
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the inner cities with a lower social background are
approached. Dropouts and refusals to participate can lead
to selection bias due to differences between participants
who remain in the study and dropouts [12]. Therefore,
questionnaires requesting the underlying causes will be
sent to the families and several research projects addres-
sing dropout issues have been initiated.
Assessments
There is a basic program that will be carried out at each
study centre visit. This program includes clinical history
(perinatal and past medical history, medications,Figure 2 Numbers of participants to be recruited in the different ageallergies, immunizations, developmental history and
family history) clinical examination, collection of blood,
hair and urine samples, anthropometry and different
age-dependent questionnaires (see Table 4). Question-
naires are completed by the parents and starting at the
age of eight years also by the child itself. They are stan-
dardized, validated, published, computerized and piloted.
Whenever possible mother, father and even the teacher
of the child are asked to answer the questionnaires sep-
arately. Additional assessments are added at different
ages or in subgroups. The development of children be-
ginning at the age of three months until 3 ½ years of age
is evaluated by psychologists using the newly developedgroups.
Figure 3 Recruitment and follow-up procedure. 1 LIFE Child HEALTH cohort and LIFE Child OBESITY cohort: annual follow-up. LIFE Child
DEPRESSION cohort: follow-up every two years. LIFE Child BIRTH cohort: follow-up the 34th to 36th week of gestation and the 3rd and 6th month
postpartum. 2 Completion of a dropout questionnaire.
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DevelopmentW (Bayley-IIIW) [13]. In close collaboration
with the developers of these scales – Pearson ClinicalFigure 4 The LIFE Child study logo.Assessments – and other study centres, LIFE Child
study will contribute to the German standardization of
this new edition. Beginning at the age of 3 ½ years, all
children attend a motor skills examination. At the age of
six years, lung function testing (spirometry), a voice
examination and a body scan are added. The 3D body
scanner (VITUS XXL 3D) is a measuring tool for a rapid
quantification of body shape [14]. In LIFE Child study, it
is used for anthropometric investigations. Within a few
seconds, the whole body of the participant is scanned
with non-hazardous laser beams and a 3D figure appears
on the attached computer screen. The results of the
body scanner will be compared to the results of the clas-
sic anthropometry to evaluate whether the body scanner
can replace measuring tape, scales and stadiometers in
the future. Another unique assessment is the voice
examination, which will allow to explore genetic and en-
vironmental effects on the voice [15]. Voice limits are
measured in a standardized fashion (sound-pressure
levels in dependence of frequency) when the participants
speak and sing. These data will provide clinically rele-
vant information about the volume and pitch range of
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have profound effects on general health and quality of
life [17]. The social impact of diseases like dental caries,
periodontal diseases and orofacial pain in children is
substantial. Worldwide more than 50 million school
hours are lost each year to dental-related illness and
especially children with lower social background are
affected [18]. Therefore, dental examinations including
jaw models and evaluation of dental caries, periodontal
disease, orofacial pain, bruxism and tongue function are
performed. In the LIFE Child OBESITY cohort (includ-
ing the control group), additional parameters such as
electrical bioimpedance, assessment of basal metabolic
rate, oral glucose tolerance test, spiroergometry and
measurement of endothelial function using EndoPATW
are assessed. The oral glucose tolerance test (oGTT)
is performed with insulin and glucose measured every
15–30 min between 0 and 120 min. It is assumed that
this approach with close measurement intervals will
allow a better insight into metabolic processes. The
EndoPATW 2000 (Itamar Medical Inc., Caesarea, Israel)
is a device to measure peripheral arterial tonometry –
PAT – signals. It has been validated and used in several
studies to analyze the reactive hyperaemia index (RHI),
which quantifies the dilatation response of peripheral
vessels to increased blood flow following suprasystolic
occlusion [19-21]. A low RHI has been shown to be
associated with endothelial dysfunction and a higher risk
for existent or future cardiovascular events [22]. Tables 1,
2, 3, 4 and 5 show all the parameters collected in the
LIFE Child study. More detailed information on the
LIFE Child study protocol is available upon request and
on our homepage (http://www.uni-leipzig-life.de) to any
researcher interested in the program.
Biological samples
In accordance with the COBRA project (Childhood
Overweight BioRepository of Australia project) the LIFE
Child study team established a unique ‘biorepository’ of
data and biological samples of the cohort [23]. Blood,
urine and hair samples are collected from each study
subject and its parents annually. The volume of the
blood withdrawal has been adjusted to the age and body
weight of the children. Some blood parameters are ana-
lyzed directly. These parameters cover several areas of
particular health interest like micronutrient deficiency,
sero-epidemiology, growth and sexual hormones and
risk indicators for different diseases (see Table 5). To
minimize the possibility of degradation, the plasma and
serum samples for future investigations are biobanked in
small aliquots (300 μl) and stored at −140°C [24]. Gen-
omic DNA, dried blood spots, paxgenes (for RNA isola-
tion and expression/eQTL studies) and immortalized
lymphocytes are stored at −80°C. At delivery umbilicalcord blood, the umbilical cord itself and placental biop-
sies are stored in the biobank. The biopsies are stored at
−80°C, while the cord blood is aliquoted and biobanked
at −140°C. Breast milk is known to contain many bio-
active hormones and peptides, which may play important
roles in neonatal health and development. For example
researchers of the LIFE Child study team could show that
infants’ body weight gain may be influenced by milk lep-
tin concentrations [25]. Breast milk is collected and
stored at −80°C from lactating mothers the third and
sixth month postpartum.
Quality management issues
For epidemiological research, accuracy and reliability of
the measurements used are extremely important consid-
erations. Quality management in the LIFE Child study
involves multiple levels of training, monitoring and feed-
back activities, including: certification of research
personnel for all specialized testing procedures and for
data entry, documentation of all procedures in a written
and web-accessible manual of procedures and ongoing
monitoring of data quality. Several feasibility studies
have been carried out to evaluate different assessments.
A pilot study was performed to test the complete study
protocol. This project with 200 normal weight and 200
obese participants was finished in December 2011. The
experiences have been applied to optimize the oper-
ational sequences of the LIFE Child study. Since the
quality of data from participants of the pilot phase was
comparable to those collected later on, data have now
been included in the total cohort. All different assess-
ments are performed and evaluated by a well-trained
team of physicians, nurses, technical assistants, psychol-
ogists, dentists, sport and nutritional scientists. Docu-
ments outlining the standard operating procedures
(SOPs) exist for all assessments. The completeness,
consistency and plausibility of all collected data are con-
trolled regularly and in a standardized fashion using
computation of the data. In addition to internal quality
management, an external scientific advisory board was
established to supervise the study.
Incidental findings and disclosure of results
Newest research technologies applied in large cohorts
may lead to unexpected results. These incidental findings
are defined as unexpected findings discovered in the
course of research but ‘beyond the aims of the study’ [26].
Policies addressing various categories of findings and
plans for their handling have been established. At the end
of each study visit the participating families are invited to
a personal conversation with one of the physicians to
receive a short feedback on the results of the routine mea-
surements, such as physical measures (weight and height).
Any results that meet the requirements of scientific
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tion or treatment measures are reported to the family and
with the parent’s consent also to the family’s primary care
physician [27,28]. Additional diagnostic or therapeutic
steps are given to the discretion of the family and fall into
the responsibility of the family’s primary care physician. In
cases of doubt whether a finding should be reported to
the families or not, the ethical advisory boards and med-
ical experts are being asked for advice and their decisions
are documented for future decision taking. When situa-
tions of suspected child abuse/neglect are encountered
the LIFE Child team is aware of legal obligations to report
this information to authorities.
Research projects
A short description of the specific aims, measurements
and projects of the LIFE Child study is given here:
1. Growth, development and health (the LIFE Child
HEALTH cohort)
Genetics and perinatal conditions such as social and
environmental determinants are major factors influen-
cing growth, development, health and disease outcomes
including all-cause mortality and cardiovascular disease
[29]. Some of the research questions that will be
addressed are:
(1) Which fetal and infant growth patterns are
associated with the development of risk factors for
non-communicable diseases such as obesity,
cardiovascular diseases and atopy?
(2) Which environmental factors and genetic variants
are determinants of normal and abnormal growth,
development and health?
(3) How are normal growth, physical activity and
cognitive development defined in modern society?
Measurements planned and biological samples collected
in the LIFE Child HEALTH cohort are listed in Table 1,4
and 5.
2. Pregnancy and offspring (the LIFE Child BIRTH cohort)
The LIFE Child study also includes a birth cohort. In
this cohort the influence of antenatal factors on growth
and neurobehavioral outcomes will be investigated. Pre-
natal visits are conducted during the 24th and the 26th
week of gestation with a follow up ten weeks later (see
Table 3). During the first year of life, data from new-
borns is collected at 3, 6 and 12 month of age. The child
is then integrated into the LIFE Child HEALTH cohort.
In order to enable and improve the collaboration with
other birth cohorts, the LIFE Child BIRTH cohort isalready listed on the website birthcohorts.net [30].
Research questions that will be addressed include:(1) What are the interactions between gestational
environmental factors (e.g. maternal diet) and
susceptibility genes in the development of non-
communicable diseases such as obesity,
cardiovascular diseases and atopy?
(2) What specific determinants underlie the differences
in birth outcomes?
(3) What are the prenatal and early postnatal determinants
of normal and abnormal growth, physical and cognitive
development?___3. Childhood overweight and obesity (the LIFE Child
OBESITY cohort)
The rates of overweight and obesity are unacceptably
high, with significant sequelae for the health and well-
being of affected children. The pathogenesis of obesity
related comorbidities such as metabolic disorders and
cardiovascular disease already starts in childhood [31].
Therefore, identifying predisposing and protective envir-
onmental and genetic factors and subsequent prevention
and therapy of early onset obesity have become a major
focus in research [32,33]. The LIFE Child OBESITY co-
hort will be established as a well-characterized cohort of
overweight and obese children and adolescents com-
pared to healthy normal weight controls (see Table 1).
All participants also undergo the complete LIFE Child
HEALTH program. For the purposes of recruitment
overweight and obesity are classified using the 90th and
97th body mass index (BMI) percentile cut-offs of Kro-
meyer-Hauschild, as these classification is routinely used
in Germany [34,35]. Worldwide several other systems
for classification, such as the World Health Organization
(WHO) criteria or the ones of the International Obesity
Task Force (IOTF) exist [36]. Therefore, the LIFE Child
study always includes a data set with raw height, weight
and BMI to enable researchers to use other classifica-
tions when it comes to data analysis. Some of the re-
search questions that will be addressed are:(1) What are the biological, genetic, social and behavioural
determinants and consequences of childhood obesity?
(2) Which specific factors lead to an increased risk of
later weight-related comorbidities?
(3) Which genetic and environmental determinants are
associated with long-term weight loss or weight























Figure 5 Steady increase of study participant numbers and
follow-up visits over time. July 2011 to August 2012.
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http://www.biomedcentral.com/1471-2458/12/1021Depressive disorders are more and more present even
in young children. The most prevalent problems are be-
havioural and emotional disorders and hyperactivity [37].
Since nowadays health sciences focus on a salutogenetic
approach, the quest for protective factors on mental devel-
opment and health has increasingly gained importance
[38]. Several genetic, demographic, psychosocial, cognitive
and biological correlates of onset and course of mental
health problems such as early-onset depression have
already been identified. Unfortunately, little is known
about the interactions of these factors [39]. Research
questions that will be addressed include:
(1) What are determinants of normal and abnormal
mental and social development?
(2) What are determinants of depressive disorders in
children, adolescents and young adults?
(3) What influences the developmental course
of emotional symptoms and affective disorders
between childhood and early adulthood?
Measurements planned in the LIFE Child DEPRESSION
cohort are listed in Table 4.
5. Atopy (the LIFE Child ATOPY cohort)
Asthma and allergies have become increasingly preva-
lent during recent years [40-42]. The rapid increase of
their prevalence in East Germany after the German re-
unification implies an association with lifestyle changes
[43]. Therefore, the family history and questionnaires
concerning atopic symptoms together with blood para-
meters like IgE concentrations specific for different
food allergens and aeroallergens are assessed in the
LIFE Child HEALTH cohort and allow to define a sub-
cohort of clinically manifested or predisposed partici-
pants. In this LIFE Child ATOPY cohort additional
questionnaires and a prick test with common allergens
will be performed. Research questions include:
(1) What is the overall incidence of atopy from birth to
adulthood?
(2) What are the underlying interactions between
environmental and genetic determinants that lead
to atopy?
Results
Close coordination and engagement of a multidisciplin-
ary team in LIFE Child successfully established proce-
dures and systems for balancing many competing study
and ethical needs. By means of quality management,
daily operating procedures have been improved before
data collection for the main study of LIFE Child started
in July 2011. Until August 31st 2012, 1,382 children andtheir families and 112 pregnant women have attended at
least one appointment in the study centre and 212
follow-up visits have already been executed. Moreover,
96 babies were enrolled at birth. In the LIFE Child DE-
PRESSION cohort 207 children (including clinic-
referred and healthy children) participated. We were
literally overwhelmed by the success of our recruitment
strategies with 534 families still being on the waiting list
for participation in the LIFE Child study. Figure 5 shows
the steady increase of participant numbers over time.
Initial data suggest that the cohort will be representative
for the population of Leipzig and indicate a high accept-
ance rate of the study program and the different assess-
ments. For example, preliminary data on the acceptance
revealed that the overall response was very positive with
89% of the children and their families planning to defin-
itely come again for follow-up. Detailed analyses on
dropout rates and the acceptance of the study program
are on the way and will be published elsewhere. Initial
data from school classes enrolled in the study show that
boys are more likely to attend lower level education
schools than girls while girls are overrepresented in the
higher educational tracts. Data on the overall frequency
of incidental findings, the gender- and age-specific distri-
bution and the frequency with which clinical action is
taken as a result of discovering an incidental finding are
going to be reported elsewhere.Discussion
Like any other comparable study, the LIFE Child study
has its strengths and limitations. Some of the main
strengths are the large sample size of the cohort, the longi-
tudinal design of the study and the broad age range. Lon-
gitudinal studies in general have many advantages
compared to cross-sectional studies like the reduction of
retrospective bias from the participants, the possibility to
take biological samples at different time points and the
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http://www.biomedcentral.com/1471-2458/12/1021monitoring of changes with age [44]. Further advantages
of the LIFE Child study are the multidisciplinarity and
close collaboration with the University of Leipzig and di-
verse research centres like the IFB, the Helmholtz centre
for environmental research and the LIFE Adult cohort.
The LIFE Child study has an open policy in regard to col-
laboration with other research groups. Compared to other
planned or recently started population-based cohort stud-
ies, the size of the LIFE Child study is not larger but the
measurements are more detailed [2,3]. For example bio-
logical samples are obtained from all participants and their
parents at each follow-up visit. By this a ‘biorepository’
containing a longitudinal collection of samples starting in
the early stages of life and childhood from each participant
will be established that provides a unique and powerful
opportunity to monitor metabolic and epigenetic changes
over time [45]. A huge variety of different assessments are
performed. Established assessments are combined with
newest technology such as the 3D body scanner. These
new methods, the combination of various different assess-
ments from many different disciplines performed annually
and the possibility to cover the entire lifespan (together
with LIFE Adult) make the LIFE Child study unique. The
main potential limitation may lie in the difficulty to main-
tain a representative cohort especially during follow-up
[46]. Due to some of our recruitment strategies, the parti-
cipants of the LIFE study will likely be characterized by a
higher educational and socio-economic status compared
to the general population. Whole school classes, especially
from inner cities, are approached to minimize this bias.
This strategy will help to recruit a sample that adequately
represents the population of Leipzig. The idea to invite
school classes is a relatively new approach in epidemiolo-
gic research. However, researchers of the LIFE Child team
already successfully performed a cross-sectional cohort
study along with regular public health service examina-
tions in a total of 2,365 healthy schoolchildren [11]. The
experiences using this sampling technique in mid-
Germany are promising and may help to improve the
response rate [47]. The aim of LIFE Child is to improve
the knowledge about normal and abnormal child growth,
development, health and disease in contemporary children
and adolescents and thus help to develop superior
strategies in the prevention and treatment of diseases.
Consequently, the results may improve the situation for
future generations of children, adolescents and adults in
Leipzig and beyond. The study will provide core material
for many research projects and the value of the collected
data in the LIFE Child study will increase over time.
Researchers from everywhere are invited to participate in
data analysis and sharing. Moreover, it is possible for
researchers to use the templates of the LIFE Child study
to generate other disease cohorts for which the LIFE
Child HEALTH cohort may contribute controls.Competing interests
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